Satraplatin's Stumble: Is Accelerated Approval Under Threat?
This article was originally published in RPM Report
Executive Summary
GPC Biotech was dealt a nasty blow when an FDA advisory committee recommended against approving satraplatin for prostate cancer until the company submits more data. The outcome left some analysts questioning the future of an important approval pathway for small biotech companies.